Open AccessActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Author(s) -
Naiyer A. Rizvi,
Julien Mazières,
David Planchard,
Thomas E. Stinchcombe,
Grace K. Dy,
Scott J. Antonia,
Leora Horn,
H. Léna,
Elisa Minenza,
B. Mennecier,
Gregory A. Otterson,
Luis Campos,
David R. Gandara,
Benjamin Levy,
Suresh Nair,
Gérard Zalcman,
Jürgen Wolf,
Pierre-Jean Souquet,
Editta Baldini,
Federico Cappuzzo,
C. Chouaïd,
Afshin Dowlati,
Rachel E. Sanborn,
Ariel López-Chávez,
Christian Grohé,
Rudolf M. Huber,
Christopher Harbison,
Christine Baudelet,
Brian Lestini,
Suresh S. Ramalingam
Publication year - 2015
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/74ry-7003
Subject(s) - nivolumab , refractory (planetary science) , medicine , cancer research , oncology , lung cancer , cancer , immunotherapy , materials science , composite material